Phase 2a Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04553406 |
Recruitment Status :
Recruiting
First Posted : September 17, 2020
Last Update Posted : January 15, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Mycobacterium Avium Complex | Drug: SPR720 Drug: Placebo Drug: Open-label SOC | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 90 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Treatment Arms 1 to 3 are masked while Treatment Arm 4 is open-label |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Partially Blinded, Placebo- and Comparator-Controlled, Multicenter, Phase 2a, Dose Ranging, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SPR720 as Compared With Placebo or Standard of Care for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease |
Actual Study Start Date : | November 10, 2020 |
Estimated Primary Completion Date : | January 2022 |
Estimated Study Completion Date : | February 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: SPR720 low dose
SPR720 500 mg (2 capsules of 250 mg SPR720 and 2 capsules of placebo) administered orally once daily for 28 days
|
Drug: SPR720
250 mg capsules |
Experimental: SPR720 high dose
SPR720 1000 mg (4 capsules of 250 mg SPR720) administered orally once daily for 28 days
|
Drug: SPR720
250 mg capsules |
Placebo Comparator: Placebo
4 capsules of placebo once daily for 28 days
|
Drug: Placebo
4 capsules of matching placebo |
Active Comparator: Standard of Care (SOC)
Clarithromycin 500-1000 mg plus ethambutol HCl 15 mg/kg po once daily or Azithromycin 250-500 mg plus ethambutol HCl 15 mg/k po once daily. Optional rifampin 600 mg or rifabutin 300 mg po once daily may be added to the SOC regimen for up to 28 days. Additional SOC treatments may be considered in consultation with the medical monitor. |
Drug: Open-label SOC
Clarithromycin 500-1000 mg plus ethambutol HCl 15 mg/kg po once daily or Azithromycin 250-500 mg plus ethambutol HCl 15 mg/k po once daily. Optional rifampin 600 mg or rifabutin 300 mg po once daily may be added to the SOC regimen for up to 28 days. Additional SOC treatments may be considered in consultation with the medical monitor. |
- Maximum plasma concentration (Cmax) [ Time Frame: From Day 1 to Day 28 ]For Treatment Arms 1, 2, and 3
- Time to reach Cmax (Tmax) [ Time Frame: From Day 1 to Day 28 ]For Treatment Arms 1, 2, and 3
- Area under the concentration-time curve from zero to tau, where tau is the dosing interval (AUC0-tau), [ Time Frame: From Day 1 to Day 28 ]For Treatment Arms 1, 2, and 3
- Accumulation ratio of SPR719 [ Time Frame: From Day 1 to Day 28 ]For Treatment Arms 1, 2, and 3
- Reported adverse events (AEs) [ Time Frame: Day 1 to Day 56 ]
- Clinically meaningful change in physical examination findings [ Time Frame: Day 1 to Day 56 ]To assess the incidents of abnormal body system assessments following 28 days of IP administration
- Concomitant medication usage [ Time Frame: Day 1 to Day 56 ]The type and frequency of medications used
- Changes from baseline in laboratory tests [ Time Frame: Day 1 to Day 56 ]To assess the incidents of abnormal hematology, biochemistry, coagulation and urinalysis assessments following 28 days of IP administration
- Clinically significant (CS) out-of-normal range laboratory tests [ Time Frame: Day 1 to Day 56 ]To assess the incidents of clinically significant abnormal hematology, biochemistry, coagulation and urinalysis assessments following 28 days of IP administration
- Shifts from baseline in selected laboratory tests using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 shift categories [ Time Frame: Day 1 to Day 56 ]
- Changes from baseline in vital sign measurements [ Time Frame: Day 1 to Day 56 ]To assess the incidents of abnormal heart rate, blood pressure and body temperature assessments following 28 days of IP administration
- 12-lead ECGs [ Time Frame: Day 1 to Day 56 ]To assess the incidents of abnormal heart rate, cardiac rhythm, PR interval, RR interval, QRS interval, QT interval and QTC interval assessments following 28 days of IP administration

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Has a diagnosis of NTM-PD due to MAC
- Had at least 1 prior positive culture (sputum or bronchoalveolar lavage) positive for MAC in the previous 6 months
- Has an induced sputum culture at screening positive for MAC by at least one of the following methods performed by the microbiology laboratory: quantitative culture on solid agar or growth on liquid media (MGIT)
- Is either treatment naïve and has not received any prior treatment for MAC, OR if previously treated for MAC, has culture evidence of persistent, recurrent, or relapsed disease and has been off therapy for at least 6 months
- In the opinion of the Investigator, is ready to initiate treatment (treatment naïve) or reinitiate treatment (previously treated) within the next 3 months, and for whom a delay, in order to participate in a placebo-controlled clinical trial, is considered reasonable and clinically acceptable
-
Had clinical signs and symptoms within the 6 weeks before the date of consent that are consistent with NTM-PD with at least two of the following:
- chronic cough
- fatigue
- frequent throat clearing
- shortness of breath (dyspnea)
- coughing up of blood (hemoptysis)
- excessive mucus (sputum) production
- fever
- night sweats
- loss of appetite
- unintended weight loss
- wheezing
- chest pain
- Has a measured forced expiratory volume in 1 second (% predicted FEV1) ≥30% on pulmonary function test within 3 months prior to consent
- Has a chest radiograph (CXR) or computed tomography (CT) scan within 6 months prior to consent with findings consistent with NTM-PD. If no CXR or CT scan is available, a CXR or CT scan should be performed at screening to confirm eligibility.
- Other inclusion criteria per protocol
Exclusion Criteria:
- Has disseminated or extrapulmonary NTM
- Has end-stage NTM-PD or treatment-refractory NTM-PD and is unlikely to respond to protocol-specified SOC treatment
- Had isolation on sputum cultures of any species of Mycobacterium other than a species included in MAC within the past 6 months
- Had prior isolation of MAC with macrolide resistance
- Has received any systemic (oral or IV) or inhaled antibiotic with activity against MAC between consent and randomization
- Has a potentially confounding underlying pulmonary disease, including but not limited to cystic fibrosis, active pulmonary malignancy (primary or metastatic), NTM-hypersensitivity disease pneumoconiosis, or another advanced lung disease with a % predicted FEV1<30%
- Other exclusion criteria per protocol

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04553406
Contact: Caroline Wass | 8572421586 | cwass@sperotherapeutics.com |
United States, Florida | |
Medical Facility | Recruiting |
Altamonte Springs, Florida, United States, 32701 | |
Medical Facility | Recruiting |
Atlantis, Florida, United States, 33462 | |
Medical Facility | Recruiting |
Clearwater, Florida, United States, 33765 | |
Medical Facility | Recruiting |
Kissimmee, Florida, United States, 34746 | |
Medical Facility | Recruiting |
West Palm Beach, Florida, United States, 33407 | |
United States, North Carolina | |
Medical Facility | Recruiting |
Charlotte, North Carolina, United States, 28207 | |
Medical Facility | Recruiting |
Mooresville, North Carolina, United States, 28117 | |
Medical Facility | Recruiting |
Winston-Salem, North Carolina, United States, 27103 | |
United States, Pennsylvania | |
Medical Facility | Recruiting |
Pittsburgh, Pennsylvania, United States, 15213 |
Study Director: | David Melnick, MD | Spero Therapeutics, Inc. |
Responsible Party: | Spero Therapeutics |
ClinicalTrials.gov Identifier: | NCT04553406 |
Other Study ID Numbers: |
SPR720-201 |
First Posted: | September 17, 2020 Key Record Dates |
Last Update Posted: | January 15, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Mycobacterium Infections Mycobacterium avium-intracellulare Infection Actinomycetales Infections |
Gram-Positive Bacterial Infections Bacterial Infections Mycobacterium Infections, Nontuberculous |